The Pivotal Role of Telomerase in Breast Cancer Therapy Resistance and Treatment Strategies

Introduction

Breast cancer remains one of the most prevalent malignancies worldwide, with therapy resistance posing a significant challenge in achieving long-term remission. Among the key molecular players influencing treatment outcomes, telomerase- a ribonucleoprotein enzyme responsible for maintaining telomere length- has emerged as a critical factor in cancer cell survival, proliferation, and resistance to therapy. Elevated telomerase activity is observed in approximately 90% of breast cancers, contributing to unlimited replicative potential and evasion of apoptosis. This article explores the mechanisms by which telomerase modulates breast cancer’s response to conventional and targeted therapies, along with emerging strategies to exploit telomerase inhibition for improved treatment efficacy.

Telomerase and Telomere Maintenance in Breast Cancer

Telomeres, the protective nucleotide repeats at chromosome ends, shorten with each cell division, eventually triggering senescence or apoptosis. In normal somatic cells, telomerase activity is negligible, but cancer cells, including breast cancer, frequently reactivate telomerase through the upregulation of its catalytic subunit, human telomerase reverse transcriptase (hTERT). This reactivation enables continuous proliferation by preventing critical telomere shortening. Studies indicate that hTERT overexpression correlates with aggressive breast cancer subtypes, such as triple-negative and HER2-positive tumors, suggesting its role in disease progression and therapy resistance.

Mechanisms of Telomerase-Mediated Therapy Resistance

Telomerase contributes to treatment resistance through multiple pathways beyond telomere elongation. First, it enhances DNA repair mechanisms, allowing cancer cells to recover from chemotherapy- and radiation-induced damage. Second, telomerase interacts with key oncogenic signaling pathways, including PI3K/AKT and Wnt/β-catenin, promoting survival even under therapeutic stress. Additionally, telomerase-positive breast cancer cells exhibit reduced susceptibility to immune surveillance, partly due to the altered expression of immune checkpoint molecules. These mechanisms collectively enable tumors to withstand standard treatments, leading to relapse and metastatic spread.

Telomerase as a Predictive Biomarker in Breast Cancer

Given its association with poor prognosis, telomerase activity and hTERT expression levels hold promise as biomarkers for predicting therapeutic response. Patients with high telomerase activity often exhibit resistance to endocrine therapies, such as tamoxifen, and conventional chemotherapies like anthracyclines and taxanes. Emerging liquid biopsy techniques now allow non-invasive monitoring of telomerase-related markers in circulating tumor cells (CTCs) and cell-free DNA, offering real-time insights into treatment efficacy and disease progression.

Targeting Telomerase in Breast Cancer Treatment

Therapeutic strategies to inhibit telomerase include direct enzyme inhibitors (e.g., imetelstat), immunotherapy (telomerase-targeted vaccines), and gene therapy approaches. Imetelstat, a competitive telomerase inhibitor, has shown promise in preclinical models by inducing telomere attrition and apoptosis in breast cancer cells. Meanwhile, telomerase vaccines, such as GV1001, aim to stimulate immune responses against hTERT-expressing tumors. Combining telomerase inhibitors with conventional therapies or immune checkpoint blockers may enhance cytotoxicity and overcome resistance mechanisms.

Challenges and Future Directions

Despite encouraging preclinical data, clinical translation of telomerase-targeted therapies faces hurdles, including off-target effects and variable patient responses. Moreover, the dynamic regulation of telomerase in cancer stem cells (CSCs) complicates the eradication of minimal residual disease. Future research should focus on optimizing combination regimens, identifying predictive biomarkers for patient stratification, and developing next-generation telomerase inhibitors with improved specificity.

Conclusion

Telomerase plays a multifaceted role in breast cancer’s resistance to therapy, making it an attractive target for novel treatment strategies. While challenges remain in translating laboratory findings to clinical practice, advancements in telomerase inhibition and biomarker-driven approaches offer hope for overcoming therapeutic resistance. Integrating telomerase-targeted interventions into existing breast cancer regimens may pave the way for more durable responses and improved survival outcomes in patients with aggressive disease.